Curiously, although the mechanisms discussed in this review support that both up‐ and downregulation of p62 can promote cancer, p62 mutations are primarily linked to skeletal and neurodegenerative diseases, with only one report linking copy gains of p62 with kidney cancer 6. This evidence concerns the gene SQSTM1 and neurodegenerative disease.